Aaron S Mansfield
Mayo Clinic in Rochester · Mayo Clinic · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aaron S Mansfield as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:50 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05530759 · Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor RemovalMayo Clinic · recruiting · Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- N/ANCT05324553 · Patient Derived Preclinical ModelsMayo Clinic · recruiting · Cancer · principal investigator
- Ph2NCT05001880 · Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaNational Cancer Institute (NCI) · recruiting · Peritoneal Malignant Mesothelioma · principal investigator
- Ph2NCT04439253 · Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph1/Ph2NCT03126630 · Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaNational Cancer Institute (NCI) · active not recruiting · Pleural Malignant Mesothelioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Mayo Clinic Network Lead Academic Participating SiteUG1CA232760 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2024 to 2026 · $1,637,205 awarded in 2026Same name and institution; not confirmed by an ID
- Blood-based biomarker of therapeutic efficacy for mesotheliomaR21CA251923 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2020 · $408,829 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT05001880
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04439253
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT04439253
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT03126630
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026Named on NCT03126630
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:50 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.N Engl J Med · 20182,998 citationsRCR 104.0
- 1,015 citationsRCR 56.5
- 772 citationsRCR 39.9
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J Med · 2023368 citationsRCR 29.4
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Lancet Oncol · 2021365 citationsRCR 19.2
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.Lancet Diabetes Endocrinol · 2021307 citationsRCR 17.7
- 248 citationsRCR 15.0
- 181 citationsRCR 20.1
- 170 citationsRCR 10.9
- 166 citationsRCR 5.9